Stocks News

LAST PRICE
28.1500
TODAY'S CHANGE (%)
Trending Up0.4000 (1.4414%)

Bid / Lots
28.0400/ 8
Ask / Lots
28.2100/ 8
Open / Previous Close
27.7800 / 27.7500
Day Range
Low 27.7800
High 28.4403
52 Week Range
Low 14.2200
High 47.9700
Volume
30,357
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Today
- Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Stockholders to Inquire about Securities Investigation, from 37 minutes ago by Accesswire
  37 minutes ago by Accesswire
  Companies Mentioned: SYRE
  NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spyre Therapeutics, Inc. ("Spyre" or "the Company") (NASDAQ:SYRE). Investors who purchased Spyre securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SYRE.
- Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Stockholders to Inquire about Securities Investigation, from 37 minutes ago by Dow Jones
  37 minutes ago by Dow Jones
  Companies Mentioned: SYRE
  
  NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spyre Therapeutics, Inc. ("Spyre" or "the Company") (NASDAQ:SYRE). Investors who purchased Spyre securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SYRE.
Yesterday
- Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Investors to Learn More About the Investigation, from 10:01AM ET on Thursday Nov 28, 2024 by Accesswire
  10:01AM ET on Thursday Nov 28, 2024 by Accesswire
  Companies Mentioned: SYRE
  NEW YORK, NY / ACCESSWIRE / November 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spyre Therapeutics, Inc. ("Spyre" or "the Company") (NASDAQ:SYRE). Investors who purchased Spyre securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SYRE.
- Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Investors to Learn More About the Investigation, from 10:01AM ET on Thursday Nov 28, 2024 by Dow Jones
  10:01AM ET on Thursday Nov 28, 2024 by Dow Jones
  Companies Mentioned: SYRE
  
  NEW YORK, NY / ACCESSWIRE / November 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spyre Therapeutics, Inc. ("Spyre" or "the Company") (NASDAQ:SYRE). Investors who purchased Spyre securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SYRE.
Nov 27, 2024
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE, from 12:01PM ET on Wednesday Nov 27, 2024 by Accesswire
  12:01PM ET on Wednesday Nov 27, 2024 by Accesswire
  Companies Mentioned: SYRE
  NEW YORK CITY, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Nov 27, 2024
- Ars Pharmaceuticals Insider Sold Shares Worth $1,411,742, According to a Recent SEC Filing, from 4:20PM ET on Wednesday Nov 27, 2024 by MT Newswires
  4:20PM ET on Wednesday Nov 27, 2024 by MT Newswires
  Companies Mentioned: SPRY
Nov 26, 2024
- Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting, from 8:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
  8:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
  Companies Mentioned: PRAX
Nov 25, 2024
- TD Cowen Initiates Viridian Therapeutics at Buy, from 8:34AM ET on Monday Nov 25, 2024 by MT Newswires
  8:34AM ET on Monday Nov 25, 2024 by MT Newswires
  Companies Mentioned: VRDN
- DJ Viridian Therapeutics Price Target Maintained With a $38.00/Share by Needham, from 7:06AM ET on Monday Nov 25, 2024 by Dow Jones
  7:06AM ET on Monday Nov 25, 2024 by Dow Jones
  Companies Mentioned: VRDN
- DJ Viridian Therapeutics Initiated at Buy by TD Cowen, from 6:19AM ET on Monday Nov 25, 2024 by Dow Jones
  6:19AM ET on Monday Nov 25, 2024 by Dow Jones
  Companies Mentioned: VRDN
Nov 22, 2024
- DJ Neumora Therapeutics Price Target Maintained With a $29.00/Share by RBC Capital, from 12:07PM ET on Friday Nov 22, 2024 by Dow Jones
  12:07PM ET on Friday Nov 22, 2024 by Dow Jones
  Companies Mentioned: NMRA
Nov 14, 2024
- DJ Viridian Therapeutics Is Maintained at Buy by HC Wainwright & Co., from 5:18AM ET on Thursday Nov 14, 2024 by Dow Jones
  5:18AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: VRDN
- ARS Pharmaceuticals Insider Sold Shares Worth $10,143,706, According to a Recent SEC Filing, from 3:18AM ET on Thursday Nov 14, 2024 by MT Newswires
  3:18AM ET on Thursday Nov 14, 2024 by MT Newswires
  Companies Mentioned: SPRY
Nov 13, 2024
- DJ Neumora Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co., from 11:59AM ET on Wednesday Nov 13, 2024 by Dow Jones
  11:59AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: NMRA
- ARS Pharmaceuticals' Q3 Net Loss Widens, from 6:58AM ET on Wednesday Nov 13, 2024 by MT Newswires
  6:58AM ET on Wednesday Nov 13, 2024 by MT Newswires
  Companies Mentioned: SPRY

Spyre Therapeutics Inc
NASDAQ:SYREUnited States

Search Criteria

Today

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Stockholders to Inquire about Securities Investigation, from 37 minutes ago by Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Stockholders to Inquire about Securities Investigation, from 37 minutes ago by Dow Jones

Yesterday

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Investors to Learn More About the Investigation, from 10:01AM ET on Thursday Nov 28, 2024 by Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Investors to Learn More About the Investigation, from 10:01AM ET on Thursday Nov 28, 2024 by Dow Jones

Nov 27, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE, from 12:01PM ET on Wednesday Nov 27, 2024 by Accesswire

Peers Headlines

Nov 27, 2024

Ars Pharmaceuticals Insider Sold Shares Worth $1,411,742, According to a Recent SEC Filing, from 4:20PM ET on Wednesday Nov 27, 2024 by MT Newswires

Nov 26, 2024

Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting, from 8:00AM ET on Tuesday Nov 26, 2024 by Dow Jones

Nov 25, 2024

TD Cowen Initiates Viridian Therapeutics at Buy, from 8:34AM ET on Monday Nov 25, 2024 by MT Newswires

DJ Viridian Therapeutics Price Target Maintained With a $38.00/Share by Needham, from 7:06AM ET on Monday Nov 25, 2024 by Dow Jones

DJ Viridian Therapeutics Initiated at Buy by TD Cowen, from 6:19AM ET on Monday Nov 25, 2024 by Dow Jones

Nov 22, 2024

DJ Neumora Therapeutics Price Target Maintained With a $29.00/Share by RBC Capital, from 12:07PM ET on Friday Nov 22, 2024 by Dow Jones

Nov 14, 2024

DJ Viridian Therapeutics Is Maintained at Buy by HC Wainwright & Co., from 5:18AM ET on Thursday Nov 14, 2024 by Dow Jones

ARS Pharmaceuticals Insider Sold Shares Worth $10,143,706, According to a Recent SEC Filing, from 3:18AM ET on Thursday Nov 14, 2024 by MT Newswires

Nov 13, 2024

DJ Neumora Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co., from 11:59AM ET on Wednesday Nov 13, 2024 by Dow Jones

ARS Pharmaceuticals' Q3 Net Loss Widens, from 6:58AM ET on Wednesday Nov 13, 2024 by MT Newswires